SCHEMBL5001920

SCHEMBL5001920

CC1CN1S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.57
HTT P42858 1/20 0.52
LMNA P02545 3/20 0.52
TSHR P16473 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
GAA P10253 3/20 0.50
HPGD P15428 1/20 0.50
HSD11B1 P28845 2/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
PKLR P30613 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP8 P22894 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5001918 1.00 L3MBTL1 (0.57) L3MBTL1HTTLMNATSHRNPSR1
SCHEMBL2305949 0.84 HSD11B1 (0.58) HTTLMNATSHRNPSR1KMT2A
SCHEMBL20298874 0.79 AKR1C3 (0.44) L3MBTL1LMNATSHRNPSR1KMT2A
SCHEMBL19013822 0.78 AKR1C3 (0.58) L3MBTL1HTTALDH1A1POLBGAA
SCHEMBL18726870 0.78 ALDH1A1 (0.63) L3MBTL1HTTLMNAKMT2AALDH1A1
SCHEMBL5001790 0.78 KMT2A (0.51) HTTLMNATSHRNPSR1KMT2A
SCHEMBL5001789 0.78 KMT2A (0.51) HTTLMNATSHRNPSR1KMT2A
SCHEMBL13950417 0.77 HSD11B1 (0.60) HTTLMNATSHRNPSR1KMT2A
SCHEMBL31471833 0.77 HSD11B1 (0.60) HTTLMNATSHRNPSR1KMT2A
SCHEMBL7235634 0.75 POLB (0.59) L3MBTL1HTTLMNATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249106-A1 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction AMGEN INC. 2008-10-09 US disclosed
US-7414134-B2 B1 bradykinin receptor antagonists AMGEN INC. (US) 2008-08-19 US disclosed
US-20060100216-A1 Novel B1 bradykinin receptor antagonists AMGEN INC. (US) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249106-A1 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction BDKRB1, BDKRB2, FPR1 L3MBTL1 2468/4885HTT 2588/4885LMNA 1965/4885
US-20060100216-A1 Novel B1 bradykinin receptor antagonists BDKRB1, BDKRB2, EDNRB L3MBTL1 1617/4885HTT 2398/4885LMNA 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.